RiMO-301 plus radiation with PD-1 therapy for head-neck cancer
Part of Cancer clinical trials.
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head-and-neck cancer that needs palliative (symptom-relieving) radiation
- Your cancer is unresectable, recurring, or has spread (metastatic), and you either already get a PD-1 drug (pembrolizumab or nivolumab) or your doctor can start one
- You have at least one tumor spot that a doctor can safely inject RiMO-301 and treat with the planned radiation plan
- The tumor spot is measurable on scans, and it is not in an area already treated with radiation recently (at least 6 months ago) or you had no serious problems from prior radiation
- You are at least 18 years old, well enough to do daily activities (ECOG 0–2), and have expected survival of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
This trial tests a new treatment for head and neck cancer that can be removed with surgery. It combines an experimental drug (RiMO-301) with targeted radiation and an immunotherapy drug (pembrolizumab) given before surgery, to see if it can shrink the tumor and improve outcomes.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
Hear when a new Head Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.